• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Makale Koleksiyonu
  • View Item
  •   DSpace@MEF
  • Fakülteler
  • İktisadi İdari ve Sosyal Bilimler Fakültesi
  • Ekonomi | Economics
  • İİSBF, EB, Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Advanced Search

Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: outcomes in a community setting

Thumbnail

View/Open

Yayıncı Sürümü_Makale (544.8Kb)

Access

info:eu-repo/semantics/closedAccess

Date

2015

Author

Dalal, Mehul R
Xie, Lin
Başer, Onur
DiGenio, Andres

Metadata

Show full item record

Citation

Dalal, M., Xie, L., Baser, O., & DiGenio, A. (January 01, 2015). Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting. Endocrine Practice, 21, 1, 68-76.

Abstract

To evaluate real-world outcomes in patients with type 2 diabetes mellitus (T2DM)receiving basal insulin, who initiate add-on therapy with a rapid-acting insulin (RAI) or aglucagon-like peptide 1 (GLP-1) receptor agonist.Data were extracted retrospectively from a U.S. health claims database. Adults withT2DM on basal insulin who added an RAI (basal+RAI) or GLP-1 receptor agonist (basal+GLP-1) were included. Propensity score matching (1 up to 3 ratio) was used to control for differencesin baseline demographics, clinical characteristics, and health resource utilization. Endpointsincluded prevalence of hypoglycemia, pancreatic events, all-cause and diabetes-relatedresource utilization, and costs at 1 year follow-up. Overall, 6,718 matched patients were included: 5,013 basal+RAI and 1,705basal+GLP1. Patients in both groups experienced a similar proportion of any hypoglycemicevent (P = .4079). Hypoglycemic events leading to hospitalization were higher in the basal+RAIcohort (2.7% vs. 1.8%; P = .0444). The basal+GLP-1 cohort experienced fewer all-cause(13.55% vs. 18.61%; P<.0001) and diabetes-related hospitalizations (11.79% vs. 15.68%;P<.0001). The basal+GLP-1 cohort had lower total all-cause health care costs ($18,413 vs.$20,821; P = .0002), but similar diabetes-related costs ($9,134 vs. $8,985; P<.0001) comparedwith the basal+RAI cohort. Add-on therapy with a GLP-1 receptor agonist in T2DM patients receiving basalinsulin was associated with fewer hospitalizations and lower total all-cause costs compared withadd-on therapy using a RAI, and could be considered an alternative to a RAI in certain patientswith T2DM, who do not achieve effective glycemic control with basal insulin.

Source

Endocrine Practice

Volume

21

Issue

1

URI

http://dx.doi.org/10.4158/EP14290.OR
https://hdl.handle.net/20.500.11779/612

Collections

  • Araştırma Çıktıları, PubMed Koleksiyonu [70]
  • Araştırma Çıktıları, Scopus İndeksli Yayınlar Koleksiyonu [429]
  • Araştırma Çıktıları, WOS İndeksli Yayınlar Koleksiyonu [470]
  • İİSBF, EB, Makale Koleksiyonu [61]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Instruction | Guide | Contact |

DSpace@MEF

by OpenAIRE

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorTitlesORCIDSubjectsTypeLanguageDepartmentCategoryPublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide|| Instruction || Library || MEF University || OAI-PMH ||

MEF University Library, İstanbul, Turkey
If you find any errors in content please report us

Creative Commons License
MEF University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@MEF:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.